AERI Aerie Pharmaceuticals Inc.

23.19
-1.38  -6%
Previous Close 24.57
Open 24.62
Price To Book 6.84
Market Cap 1,065,331,045
Shares 45,939,243
Volume 866,547
Short Ratio
Av. Daily Volume 917,621

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced March 12, 2019.
Roclatan
Glaucoma
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
Rhopressa
Glaucoma
Phase 1/2 trial to be initiated 3Q 2019.
AR-13503
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Phase 2 trial initiated March 2019.
AR-1105
Macular edema due to RVO (retinal vein occlusion)
Phase 3 top-line data due 1H 2020.
Roclatan - Mercury 3
Open Angle Glaucoma

Latest News

  1. Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT
  2. This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
  3. Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
  4. Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
  5. Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript
  6. Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
  7. Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
  8. Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know
  9. Analysts Recommend Buying These 2 Falling Knives
  10. Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
  11. Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
  12. Hatteras Ventures-backed firm adds fresh round of capital
  13. How a Durham firm stands to benefit from an unexpected break in a Japanese trial
  14. Aerie Completes Enrollment Under Rhopressa Study in Japan
  15. Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
  16. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  17. Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy?
  18. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  19. Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT
  20. Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting